PURE Bioscience Establishes Distribution in India
Enviroguard has been approved by the Central Insecticides Board and Registration Committee of the Directorate General of Health Sciences. This approval allows Pure-Enviro Biotech to immediately market its SDC-based Enviroguard disinfectant in India.
J.W. Cook, CEO of Pure-Enviro Biotech, stated, “With more than 1.1 billion people equaling 17% of the world population, India is the most populous democracy in the world. The Delhi metropolitan area alone has more than 17 million residents, and we see a serious need and incredible potential for Enviroguard as a solution to multiple public health issues, including hospital disinfection, food safety and periodic outbreaks of bird flu.
“From powerful government officials responsible for districts of massive populations, to mothers and fathers caring for their families, citizens around the world share mounting concern for safety and the environment. Other products currently available in India which work to combat the potential dangers of human pathogens simply cannot compare to the safety and efficacy of Enviroguard. We are launching Enviroguard initially in New Delhi and the surrounding areas and intend to broaden distribution to other regions by leveraging our anticipated success in the capital city.”
Michael L. Krall, President and CEO of PURE Bioscience, commented, “Obviously, establishing a distributor in India represents a significant milestone in our quest to create a new worldwide standard in disinfectants. Early feedback from Pure-Enviro Biotech leads us to believe that its political contacts and established business channels should lead to initial revenues during the current fiscal year.”
Pure-Enviro Biotech’s SDC-based Enviroguard disinfectant carries a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a 2-minute kill time on some resistant strains of bacteria, a 10-minute kill time on fungi, a 30-second kill time on HIV Type I, and a 10-minute kill time on other pathogenic viruses.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact:
Investor Contact: Bibicoff + MacInnis, Inc. Terri MacInnis, Dir. of Investor Relations 818-379-8500 terri@bibimac.com or PURE Media Contact: Gutenberg Communications Suzanne Matick 831-479-1888 Suzanne@gutenbergpr.com